Implanon

Contraceptive implant therapy, Birth Control, Reproductive Age + 1 more
Treatment
1 FDA approval
20 Active Studies for Implanon

What is Implanon

EtonogestrelThe Generic name of this drug
Treatment SummaryEtonogestrel is a synthetic hormone used to make medicine to treat female reproductive issues. It is a metabolite of a drug called desogestrel and was developed by Merck subsidiary Organon in 2001. It was approved by the FDA that same year.
NuvaRingis the brand name
image of different drug pills on a surface
Implanon Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
NuvaRing
Etonogestrel
2001
15

Approved as Treatment by the FDA

Etonogestrel, otherwise called NuvaRing, is approved by the FDA for 1 uses such as Contraceptive implant therapy .
Contraceptive implant therapy

Effectiveness

How Implanon Affects PatientsEtonogestrel works by blocking the release of a reproductive hormone called luteinizing hormone. This prevents ovulation and makes it harder for sperm to enter the uterus and fertilize an egg. In clinical trials, etonogestrel had a 100% success rate in preventing pregnancy over 3 years. When the implant was removed, normal periods returned within 90 days in 91% of people and fertility returned quickly, with 20 reported pregnancies within 3 months of implant removal. The implant releases 40 mcg of etonogestrel daily and typically provides effective contraception for 3 years. Its failure rate is reported to be 0.
How Implanon works in the bodyEtonogestrel attaches to progesterone and estrogen receptors in the reproductive tract, breast, pituitary, and hypothalamus. This process reduces the production of hormones that control ovulation, resulting in contraceptive effects.

When to interrupt dosage

The suggested measure of Implanon is contingent upon the diagnosed state, including Birth Control, Reproductive Age and Contraceptive implant therapy. The degree of dosage is contingent upon the technique of delivery (e.g. Subcutaneous or Insert, extended release) as listed in the table beneath.
Condition
Dosage
Administration
Contraceptive implant therapy
11.7 mg, , 11.4 mg, 0.012 mg/hour, 68.0 mg
Insert, extended release - Vaginal, Vaginal, , Insert, extended release, Ring - Vaginal, Ring, Implant, Implant - Subcutaneous, Subcutaneous
Birth Control
11.7 mg, , 11.4 mg, 0.012 mg/hour, 68.0 mg
Insert, extended release - Vaginal, Vaginal, , Insert, extended release, Ring - Vaginal, Ring, Implant, Implant - Subcutaneous, Subcutaneous
Reproductive Age
11.7 mg, , 11.4 mg, 0.012 mg/hour, 68.0 mg
Insert, extended release - Vaginal, Vaginal, , Insert, extended release, Ring - Vaginal, Ring, Implant, Implant - Subcutaneous, Subcutaneous
Hormonal Contraception
11.7 mg, , 11.4 mg, 0.012 mg/hour, 68.0 mg
Insert, extended release - Vaginal, Vaginal, , Insert, extended release, Ring - Vaginal, Ring, Implant, Implant - Subcutaneous, Subcutaneous

Warnings

Implanon has 27 contraindications, so it must not be employed with any of the conditions enumerated in the table below.Implanon Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Etonogestrel may interact with Pulse Frequency
Pulmonary Embolism
Do Not Combine
undiagnosed abnormal genital bleeding
Do Not Combine
Coronary Disease
Do Not Combine
Liver Failure, Acute
Do Not Combine
Hypersensitivity
Do Not Combine
Atrial Fibrillation
Do Not Combine
Metrorrhagia
Do Not Combine
Hereditary Angioedema Type III
Do Not Combine
diabetes mellitus with vascular disease
Do Not Combine
valvular thrombogenesis
Do Not Combine
Thrombosis
Do Not Combine
Smoking
Do Not Combine
Stroke
Do Not Combine
Pulmonary Embolism
Do Not Combine
Breast
Do Not Combine
Deep Vein Thrombosis
Do Not Combine
Thromboembolism
Do Not Combine
Liver Neoplasms
Do Not Combine
Congenital hypercoagulation
Do Not Combine
Breast
Do Not Combine
Hypertensive disease
Do Not Combine
Liver Neoplasms
Do Not Combine
Hypersensitivity
Do Not Combine
Breast Cancer
Do Not Combine
Venous Thrombosis
Do Not Combine
Aphasia, Acquired
Do Not Combine
There are 20 known major drug interactions with Implanon.
Common Implanon Drug Interactions
Drug Name
Risk Level
Description
Tranexamic acid
Major
Etonogestrel may increase the thrombogenic activities of Tranexamic acid.
Abacavir
Minor
Etonogestrel may decrease the excretion rate of Abacavir which could result in a higher serum level.
Acetohexamide
Minor
The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Etonogestrel.
Aclidinium
Minor
Etonogestrel may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine
Minor
Etonogestrel may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Implanon Toxicity & Overdose RiskThe toxic dose of oral etonogestrel in rats is greater than 2000mg/kg. If a person takes more than one implant, the extra implant should be removed. There is no evidence that etonogestrel is linked to cancer, genetic mutations, or fertility problems.
image of a doctor in a lab doing drug, clinical research

Implanon Novel Uses: Which Conditions Have a Clinical Trial Featuring Implanon?

A total of 38 active studies are currently assessing the potential of Implanon for Birth Control, Contraceptive Implant Therapy and Hormonal Contraceptive interventions.
Condition
Clinical Trials
Trial Phases
Hormonal Contraception
0 Actively Recruiting
Reproductive Age
0 Actively Recruiting
Contraceptive implant therapy
0 Actively Recruiting
Birth Control
22 Actively Recruiting
Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 2

Implanon Reviews: What are patients saying about Implanon?

5Patient Review
1/19/2017
Implanon for Birth Control
I had the implant for 2 years and it was great. I decided to get it removed because we are ready to start a family. I had a period almost every 6 months, for a full week, which was really manageable.
5Patient Review
11/8/2016
Implanon for Birth Control
I highly recommend this form of birth control! I got it inserted with minimal pain and it stopped my period, which was amazing. If you're looking for an effective method of birth control that doesn't require taking a pill every day or dealing with too much pain, this is definitely the way to go!
5Patient Review
1/15/2016
Implanon for Birth Control
I've had the implant for a little over two years and so far, it's been great! I have very light spotting 2-3 days once every couple of months, but other than that, no period. It's been really nice not having to remember to take something or worry about it falling out.
5Patient Review
9/15/2016
Implanon for Birth Control
I've been using Implanon for seven years now, and it's fantastic. I love that I don't have to worry about any negative side effects or bleeding.
5Patient Review
4/21/2022
Implanon for Birth Control
I got the implanon in March 2020 and I'm really happy with it so far. My periods aren't as regular as they used to be, but that's to be expected. The nausea has been tough to deal with, especially after sex, but hopefully it means the implant is working well. Overall, this is the best birth control method I've tried!
5Patient Review
5/1/2022
Implanon for Birth Control
I've had two implants since 2014 and my third one's term is up in a year. I have light flow that lasts a little longer; it went from 2-3 days to 5-7 days. I haven't had any other side effects that are cause for concern.
4.3Patient Review
10/1/2016
Implanon for Birth Control
I liked how this product worked in terms of protection, but unfortunately it had some not-so-great side effects. I developed acne and vaginal dryness/swelling/itching, so I'm going to be getting it removed as soon as possible.
4Patient Review
10/12/2021
Implanon for Birth Control
On average, I bled for seven days with this treatment and my menstrual cycle shortened to 23-26 days.
3Patient Review
11/13/2019
Implanon for Birth Control
I had an implant put in November 2018, and by January 2019 I started having severe headaches. In March, my eyesight also began to deteriorate--at first I thought it was just from staring at a computer all day, but it turns out the pressure the implant was putting on my brain was causing my optic nerves to swell. So if you're experiencing any of these symptoms, please go see a doctor.
2Patient Review
11/5/2018
Implanon for Birth Control
Since I began this treatment, I've noticed some unwanted side effects like tingling in my breasts and back, as well as spotting and breast tenderness. I'm not sure if it's just anxiety though. Has anyone else experienced anything similar?
1Patient Review
5/16/2022
Implanon for Birth Control
This medicine ruined my life. I had to endure 15 years of abuse because of it, all because the doctor asked my wife if she wanted it when she was just 19 years old. My family is destroyed because of this drug, and I will never forgive those who created it.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about implanon

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How does Implanon work in the body?

"The implant is a contraception method that prevents the ovaries from releasing an egg each month. It also thickens the fluid around the cervix, making it harder for sperm to enter and fertilize an egg."

Answered by AI

When was Implanon discontinued?

"Implanon has been discontinued and replaced by Nexplanon as of October 2010 in order to reduce the risk of insertion errors."

Answered by AI

Whats the difference between Implanon and Nexplanon?

"The main difference between Implanon and Nexplanon is that Nexplanon has two extra safety features to help ensure proper insertion. Nexplanon has now replaced Implanon and Implanon is no longer being manufactured."

Answered by AI

What are Implanon side effects?

"You may experience nausea, stomach cramping/bloating, dizziness, headache, breast tenderness, acne, hair loss, weight gain, or vaginal irritation/discharge. You may also experience pain, bruising, numbness, infection, or scarring at the site where the rod is placed."

Answered by AI

Clinical Trials for Implanon

Image of University of California, San Diego in La Jolla, United States.

Lidocaine for Pain Control in Birth Control

18 - 50
Female
La Jolla, CA
The goal of this research study is to learn more about how different uses of a numbing medication might affect pain levels while getting an IUD placed. The investigators are also studying participants opinions of their clinicians' empathy. The investigators are inviting patients who arrive at their clinic visit seeking an IUD. Usually, at University of California, San Diego (UCSD), for patients who have never delivered a baby, clinicians use a buffered paracervical block for before IUD placement. The purpose of this research study is to investigate whether a "buffered" (2 cc of sodium bicarbonate, 18 cc of 1% lidocaine) paracervical block (numbing medication given on both sides of the cervix) is effective in reducing pain during IUD placement in individuals with prior C-sections, the difference between buffered and unbuffered for nulliparous patients, and whether a medicated gel reduces pain with the paracervical block.
Recruiting
Paid Trial
University of California, San DiegoSheila K Mody, MD, MPH
Image of EmpoweRx, Inc in Del Mar, United States.

HAPPI Software for Birth Control Access

18+
All Sexes
Del Mar, CA
The goal of this clinical trial is to learn if use of the HAPPI software can improve pharmacist-provided birth control services. The main questions it aims to answer are: 1. Does the HAPPI software make it easier for pharmacists to provide birth control services in their pharmacy? 2. Does the HAPPI software make it easier for patients to access birth control? Researchers will compare pharmacists' implementation and patients' access when using the HAPPI software and when not using the HAPPI software to see if the software improves implementation and access. Participants will include pharmacists and patients. Pharmacists will be asked to provide birth control services as normal while using the HAPPI software. Patients will be asked to receive birth control services from a pharmacist as normal, while using the HAPPI software.
Recruiting
Has No Placebo
EmpoweRx, Inc
Image of Calabasas Pharmacy in Calabasas, United States.

Electronic Health Record Platform for Birth Control

18 - 51
Female
Calabasas, CA
Hormonal contraceptives are medications that require a prescription, traditionally from a physician or advanced practice provider. Over the past decade, pharmacists have gained the authority to prescribe contraceptives in many states, allowing patients to access these medications directly in pharmacies without first seeing another healthcare provider. The Pharmacist Resource to Implement Services as Modules (PRISM) is an Electronic Health Record platform designed to streamline workflows and provide clinical decision support, making it easier and safer to deliver clinical services in community pharmacies. This pilot study will evaluate patient-reported outcomes for women receiving contraceptive services from pharmacists using the PRISM platform at five community pharmacies across the United States over a 12-week period. The study will assess the quality of care, contraception continuation and failure rates, side effect rates, preventative healthcare utilization, and overall patient experience with pharmacy contraceptive services.
Waitlist Available
Has No Placebo
Calabasas Pharmacy (+4 Sites)OvaryIt, LLC
Have you considered Implanon clinical trials? We made a collection of clinical trials featuring Implanon, we think they might fit your search criteria.Go to Trials
Image of Jackson State University/Department of Behavioral & Environmental Health in Jackson, United States.

PEN-3 Intervention for Postpartum Depression

18 - 45
Female
Jackson, MS
Maternal mortality in the United States is higher than in peer nations and has not decreased since 1990. Beyond mortality, severe maternal mortality impacts far too many women. Not only are these high rates alarming, but notable racial/ethnic and socioeconomic disparities exist. These inequities are highly regional, with women living in the rural southeast part of the United States, including the Mississippi Delta, having the highest rates of maternal mortality and morbidity. Unfortunately, these disparities have proven to be stubbornly resistant to interventions, necessitating an innovative multifaceted approach focused on community practice, building trust, and prioritizing patient voices. To meet this need, this proposal aims to establish the Mississippi Delta Research Center of Excellence for Maternal Health with the goal of addressing preventable maternal mortality, decreasing severe maternal morbidity, and promoting maternal health equity in partnership with the Mississippi Delta community. This patient-clinical linkages intervention study will evaluate the effectiveness of a multilevel and multisector communication and health literacy strategy to increase trust and engagement in postpartum healthcare among women in the Mississippi Delta, with a specific focus on Black women, their families, and their communities. These research projects both have the overarching goal of partnering with the community to determine and meet the needs of pregnant and postpartum women in the Mississippi Delta and address the disparities within maternity health and health care outcomes.
Recruiting
Has No Placebo
Jackson State University/Department of Behavioral & Environmental HealthMary Shaw, PhD
Image of University of Colorado Anschutz Medical Campus in Aurora, United States.

Birth Control Pills and DNA Interaction

18 - 45
Female
Aurora, CO
The goal of this clinical trial is to evaluate how differences in specific parts of our DNA can influence how individual bodies break down the hormones contained within oral contraceptive pills, which could affect how well these birth control pills work to prevent pregnancy. The investigators are also interested in exploring how these differences in our DNA can also explain why patients taking the exact same formulation of birth control pill will experience very different side effects. The main questions it aims to answer are: * Do individuals with the CYP3A7\*1C variant have increased metabolism of both desogestrel and ethinyl estradiol when taking a combined oral contraceptive pill? * Do individuals with the CYP3A7\*1C variant experience higher rates of breakthrough ovulation while taking a desogestrel/ethinyl estradiol combined oral contraceptive pill? * What novel genetic loci are associated with alterations in steroid hormone pharmacokinetics and pharmacodynamics among a larger cohort of combined oral contraceptive pill users? Participants will take a specific formulation of combined oral contraceptive pill (desogestrel/ethinyl estradiol) and undergo the following procedures: * Blood draw to measure the amount of progestin and estrogen in their system from the combined oral contraceptive pill * Questionnaires to assess side effects possibly caused by the combined oral contraceptive pill * Blood draw to measure endogenous hormone levels and biomarkers that may be affected by the combined oral contraceptive pill * A transvaginal ultrasound to measure any ovarian follicles (optional procedure)
Phase 4
Recruiting
University of Colorado Anschutz Medical Campus (+2 Sites)Aaron M Lazorwitz, MD, PhD
Have you considered Implanon clinical trials? We made a collection of clinical trials featuring Implanon, we think they might fit your search criteria.Go to Trials
Image of Greater Boston Health Center in Boston, United States.

SBIRT for Alcohol and Substance Use Disorders

18+
All Sexes
Boston, MA
The goal of this clinical trial is to test the effectiveness of evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) among adult patients who screen positive to one or more risky alcohol or substance use behaviors while seeking care at a sexual and reproductive health (SRH) clinic. The main questions it aims to answer are: * Does SBIRT impact patients' alcohol and substance use, SRH, mental health, physical health, quality of life, and wellbeing? * Does SBIRT effectiveness differ by ethnicity, socioeconomic status, age, gender, and urbanicity? * Does SBIRT effectiveness differ by delivery mode (in-person vs. telemedicine)? Participants will receive in-person and telemedicine SBIRT, or usual care. Participants will complete surveys at interviews at baseline, 30 days, and 3 months. Researchers will compare patients who received SBIRT to patients who receive usual care to see if patients who receive the SBIRT intervention have a greater reduction in negative outcomes as compared to those who receive usual care. In this setting, usual care consists of basic quantity and frequency questions asked inconsistently as part of the admission process and varying by provider, with no standardized approach to screening, treatment, follow-up, or referral.
Recruiting
Has No Placebo
Greater Boston Health Center (+3 Sites)Kelli S Hall, MD
Image of OHSU in Portland, United States.

Progestin Contraceptives for Birth Control Effects

18 - 40
Female
Portland, OR
The purpose of the study is to learn more about menstrual changes in progestin contraception users. The investigators are hoping to find out what changes in the endometrium lead to different bleeding patterns during the first year of progestin contraception use. Participants will choose to receive the contraceptive implant (Etonogestrel implant also called Nexplanon) or the contraceptive injectable (Depo-medroxyprogesterone acetate (DMPA) also called Depo-Provera) for up to 12 months. They will be asked to have 4 endometrial biopsies over the course of the study, as well as blood draws, physical exams, and pregnancy tests. Participants will also use a daily text message or email diary to report bleeding patterns. This study's plan is to comprehensively phenotype bleeding patterns and profile the entire endometrium using single-cell RNA seq data (sCRNAseq).
Phase < 1
Recruiting
OHSUAlison Edelman, MD
Have you considered Implanon clinical trials? We made a collection of clinical trials featuring Implanon, we think they might fit your search criteria.Go to Trials